Bio-Techne Corporation
Arbitration Ruling in Favor of Former Executive Requires Company to Pay Approximately $37 Million
Summary
On February 26, 2025, an arbitrator ruled in favor of Charles R. Kummeth, the former President and Chief Executive Officer of Bio-Techne Corporation, in a dispute over the expiration dates of stock options he was granted. The arbitrator determined that an administrative error by the company led to the incorrect expiration date of the options, and ordered the company to pay Mr. Kummeth approximately $35,978,000, along with interest, legal fees, and costs totaling approximately $1,214,000. This ruling follows a demand for arbitration submitted by Mr. Kummeth based on the contention that he would have exercised the options if not for the administrative error. The decision was rendered under the terms of the award agreements governing the options.
Profitelligence Alerts
Get alerts for TECH
Be first to know when Bio-Techne Corporation files with the SEC.
Filing Categories
Advertisement
About Bio-Techne Corporation
Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.
Official SEC Documents
Advertisement